“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Vyvanse (lisdexamfetamine)

Vyvanse (lisdexamfetamine) General Information Vyvanse (lisdexamfetamine) is a unique extended-release formulation of dextroamphetamine (d-amphetamine). The extended release is achieved through modification of the active molecule dextroamphetamine to form lisdexamfetamine, which is inactive. After Vyvanse is taken, it is rapidly absorbed and distributed to the liver, where it is converted back to the active stimulant, dextroamphetamine. The time to absorb and convert lisdexamfetamine to dextroamphetamine essentially makes Vyvanse an extended-release formulation of dextroamphetamine. Upon activation, Vyvanse is similar to Dexedrine Spansules (dextroamphetamine extendedrelease capsules) and has a duration of action of 8­12 hours. The use of a medication for its approved indications is called its labeled use. In clinical practice, however, physicians often prescribe medications for unlabeled ("off-label") uses when published clinical studies, case reports, or their own clinical experiences support the efficacy and safety of those treatments. Vyvanse is approved by the U.S. Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactivity disorder (ADHD). Physicians, however, may also use it to treat narcolepsy, a condition characterized by daytime somnolence, in which the person periodically falls into a deep sleep during the day. Because Vyvanse is a stimulant, it is a closely regulated controlled substance. The physician must write a new http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Vyvanse (lisdexamfetamine)

Abstract

General Information Vyvanse (lisdexamfetamine) is a unique extended-release formulation of dextroamphetamine (d-amphetamine). The extended release is achieved through modification of the active molecule dextroamphetamine to form lisdexamfetamine, which is inactive. After Vyvanse is taken, it is rapidly absorbed and distributed to the liver, where it is converted back to the active stimulant, dextroamphetamine. The time to absorb and convert lisdexamfetamine to dextroamphetamine essentially makes Vyvanse an extended-release formulation of dextroamphetamine. Upon activation, Vyvanse is similar to Dexedrine Spansules (dextroamphetamine extendedrelease capsules) and has a duration of action of 8­12 hours. The use of a medication for its approved indications is called its labeled use. In clinical practice, however, physicians often prescribe medications for unlabeled ("off-label") uses when published clinical studies, case reports, or their own clinical experiences support the efficacy and safety of those treatments. Vyvanse is approved by the U.S. Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactivity disorder (ADHD). Physicians, however, may also use it to treat narcolepsy, a condition characterized by daytime somnolence, in which the person periodically falls into a deep sleep during the day. Because Vyvanse is a stimulant, it is a closely regulated controlled substance. The physician must write a new
Loading next page...
/lp/american-psychiatric-publishing-inc-book/vyvanse-lisdexamfetamine-ehKNOWsu0m

Sorry, we don't have permission to share this article on DeepDyve,
but here are related articles that you can start reading right now: